Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - CollaGenex Pharmaceutical (NasdaqNM:CGPI)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials | Reports
Recent Events
Aug 31Price hit new 52-week high ($10.00)
Aug 27Conference call: CollaGenex Pharmaceuticals Call On Atrix Laboratories Marketing Agree
Location
41 University Drive
Newtown, PA 18940
Phone: (215) 579-7388
Fax: (215) 579-8577
Employees (last reported count): 146
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 80%
·Over the last 6 months:
 · one insider buy; 1,000  shares
 · 4 insider sells; 33.0K shares
  (0.4% of insider shares)
·Institutional: 47% (238% of float)
(33 institutions)
·Net Inst. Selling: 245.0K shares (+5.15%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
CollaGenex Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on providing medical therapies to the dental market. The Company's first product, Periostat, is an orally administered, prescription pharmaceutical product and is the first and only pharmaceutical to treat adult periodontitis by inhibiting the enzymes that destroy periodontal support tissues. In December 2000 and February 2001, the United Kingdom Medicines Control Agency and the United States Food and Drug Administration, respectively, granted marketing approval for a new tablet formulation of Periostat which is smaller, easier to swallow and offers manufacturing cost advantages. Currently, the Company is also marketing Vioxx, a prescription non-steroidal anti-inflammatory drug developed by Merck & Co., Inc. that the Company promotes for the treatment of acute dental pain, and Denavir, a prescription drug owned by Novartis Pharmaceuticals Corporation for the treatment of cold sores.
More from Market Guide: Expanded Business Description

Financial Summary
CollaGenex Pharmaceuticals is pharmaceutical company focused on providing innovative medical therapies for the treatment of periodontitis and other pathologies characterized by the progessive degradation of the body's connective tissues. For the six months ended 6/30/01, revenues rose 20% to $15.7 million. Net loss before acct. change applicable to Common rose 26% to $6.2 million. Results reflect higher sales of Periostat, offset by increased advertising costs.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Brian Gallagher, Ph.D., 53
Chairman, Pres, CEO
$438K--  
Nancy Broadbent, 45
CFO, Treasurer, Sec.
254K$19K
Robert Ashley, 43
Sr. VP
279K134K
Douglas Gehrig, 56
VP of Sales
244K--  
David Pfeiffer, 38
VP of Marketing
304K--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:CGPIAs of 31-Aug-2001
Price and Volume
52-Week Low
on 8-Dec-2000
$2.75 
Recent Price$10.00 
52-Week High
on 31-Aug-2001
$10.00 
Beta0.66 
Daily Volume (3-month avg)20.4K
Daily Volume (10-day avg)12.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change+3.2%
52-Week Change
relative to S&P500
+38.5%
Share-Related Items
Market Capitalization$105.5M
Shares Outstanding10.6M
Float2.10M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.65 
Earnings (ttm)-$1.18 
Earnings (mrq)-$0.29 
Sales (ttm)$2.87 
Cash (mrq)$0.68 
Valuation Ratios
Price/Book (mrq)15.33 
Price/EarningsN/A 
Price/Sales (ttm)3.48 
Income Statements
Sales (ttm)$26.9M
EBITDA (ttm)-$9.54M
Income available to common (ttm)-$11.1M
Profitability
Profit Margin (ttm)-34.9%
Operating Margin (ttm)-36.4%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-68.77%
Return on Equity (ttm)-141.19%
Financial Strength
Current Ratio (mrq)2.06 
Debt/Equity (mrq)0.01 
Total Cash (mrq)$7.19M
Short Interest
As of 8-Aug-2001
Shares Short4,000 
Percent of Float0.2%
Shares Short
(Prior Month)
9,000 
Short Ratio0.21 
Daily Volume19.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.